AEI lets me spend up to a day a week working on outside matters. I hadn’t done any litigating in a while, so when a pro bono opportunity for a good cause presented itself, I took it. Many other bloggers have already spoken on the issues presented by Abigail Alliance v. von Eschenbach, regarding the circumstances under which the FDA has the constitutional power to bar terminally-ill patients from being able to take potentially life-saving doctor-recommended drugs that have achieved Phase 1 approval, but have yet to receive Phase 2 approval from the FDA. (E.g., Jonathan Adler, Derek Lowe, Hans Bader, Orin Kerr, Eugene Volokh, Randy Barnett, Alex Tabarrok.) A 2-1 panel of the D.C. Circuit put limits on the FDA’s powers, but the full D.C. Circuit vacated for en banc review. With the able assistance of attorneys at O’Melveny & Myers LLP, Jack Calfee and I put together a group of all-star economists—Calfee, Dan Klein, Marginal Revolution blogger Alex Tabarrok, Ben Zycher, and one of my heroes, Sam Peltzman—and submitted an amicus brief on their behalf to the D.C. Circuit. While the case presents interesting issues of the due process clause and constitutional standing, the brief focuses on the economic issues underlying FDA drug regulation and the effect of the original panel’s decision on drug and medical safety.
OT: Abigail Alliance v. von Eschenbach
AEI lets me spend up to a day a week working on outside matters. I hadn’t done any litigating in a while, so when a pro bono opportunity for a good cause presented itself, I took it. Many other bloggers have already spoken on the issues presented by Abigail Alliance v. von Eschenbach, regarding the […]
3 Comments
Nice work. If it were up to me, I’d allow terminally ill patients to take whatever the hell they want, regardless of what the FDA says.
JL,
For once, we agree!
I agree the FDA is a monster and its function has become limiting liability and not science – give themwhatever might give them a chance